• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Schering completes Diatide purchase

Article

The radiopharmaceutical industry was further consolidated last month when Schering AG’s subsidiary, Schering Berlin, announced that it has completed the purchase of 94% of the outstanding shares of peptide imaging agent developer Diatide of

The radiopharmaceutical industry was further consolidated last month when Schering AG’s subsidiary, Schering Berlin, announced that it has completed the purchase of 94% of the outstanding shares of peptide imaging agent developer Diatide of Londonderry, NH. Schering Berlin’s tender offer, made through its subsidiary, BXA Acquisition, in September (SCAN 9/29/99), expired Oct. 22 without challenge. Schering Berlin will acquire the remaining untendered Diatide shares under another merger agreement that does not require shareholder approval. The deal is estimated at $130 million, and should be advantageous to both firms: While Diatide gains marketing and financial support, Schering gains access to Diatide’s R&D pipeline.

Recent Videos
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Related Content
© 2025 MJH Life Sciences

All rights reserved.